STAAR Surgical

STAAR Surgical Co. engages in the development, manufacture, production, marketing, and sale of implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It specializes in refractive and cataract solutions. Its products include intraocular lens and implantable collamer lens. The company was founded in 1982 and is headquartered in Lake Forest, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

STAAR Surgical reports robust Q4 performance and eyes U.S. growth

STAAR Surgical's Q4 2022 earnings call highlighted strong performance, growth opportunities in key markets, and strategic investments for future success. Despite challenges in China, the company remains optimistic about market recovery and growth prospects. With a focus on EVO lens adoption and increased investments, STAAR is well-positioned for continued growth and market expansion.

STAAR Surgical excels in Q1 with strong global sales growth

STAAR Surgical's Q1 2023 earnings call highlighted robust global sales growth, positive market reception, and strategic investments for future expansion. The company aims to strengthen its market position through targeted growth strategies and operational enhancements.

STAAR Surgical reports record Q2 sales, eyes global expansion

STAAR Surgical's Q2 2023 performance showcased record sales and growth, driven by the EVO family of ICLs.
The company's strong presence in APAC, particularly China, and confidence in high-growth outlook are notable.
Challenges include market declines and pricing dynamics, but opportunities lie in global expansion and strategic initiatives.
Balancing growth and profitability remains a focus, with ongoing efforts to enhance market presence and address challenges.

STAAR Surgical reports resilient Q3 performance amidst market challenges

STAAR Surgical's Q3 2023 performance reflects continued growth in ICL sales despite challenges.
The company is navigating macroeconomic headwinds while focusing on market-building initiatives.
Despite a decline in operating income, STAAR remains confident in its growth prospects.
STAAR's strategic focus on new products and market expansion positions it for future success.

STAAR Surgical posts robust Q4 results, eyes global expansion opportunities

STAAR Surgical's strong financial performance and strategic initiatives position the company for continued growth and market leadership.
Challenges from market competition and macroeconomic factors require careful navigation, but opportunities in expanding markets and operational enhancements offer avenues for growth.
With a focus on innovation, profitability, and global expansion, STAAR is poised to capitalize on market trends and drive sustainable growth in the coming years.

STAAR Surgical surpasses Q1 sales targets, eyes global expansion

STAAR Surgical's Q1 2024 performance exceeded expectations, driven by strong global sales growth and strategic milestones. Challenges include addressing discrepancies in sales and unit growth. The company is poised to capitalize on opportunities in China, surgeon training, and international expansion.

STAAR Surgical posts robust Q2 results, eyes global expansion

STAAR Surgical's Q2 2024 performance reflects strong sales growth, improved profitability, and a positive outlook for fiscal 2024.
The company's strategic strengths in global market expansion and innovation position it well for future growth and achieving long-term sales targets.
Challenges in managing operating expenses and sustaining growth rates in key markets require continued strategic focus and operational efficiency.
Opportunities in expanding market presence, driving innovation, and leveraging financial strength present avenues for sustained growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The firm offers implantable lenses for the eye and accessory delivery systems. Its products include refractive and cataract solutions through the Collamer brand. The company was founded in 1982 and is headquartered in Lake Forest, CA.

STAAR Surgical Company (STAA) CEO Caren Mason on Q2 2019 Results - Earnings Call Transcript

Staar Surgical (STAA) delivered earnings and revenue surprises of 40.00% and -1.09%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Staar Surgical (STAA) Beats Q2 Earnings Estimates

Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Staar Surgical (STAA) Reports Next Week: Wall Street Expects Earnings Growth

Stock fell as much 22% on news the FDA rejected its application to market 'EVO' lenses in the United States.

STAAR Surgical Company: Down On FDA Disclosure, But Not Out

Clean Harbors

Great Lakes Dredge & Dock

Herman Miller

New job additions across business services, construction and healthcare were prominent in April.

4 Stocks to Buy From Sectors With Top Job Gains

STAAR Surgical Company (STAA) CEO Caren Mason on Q1 2019 Results - Earnings Call Transcript

News for STAAR Surgical Stock (STAA)